Quantum Symmetries and Marginal Deformations

We study the symmetries of the N=1 exactly marginal deformations of N=4 Super Yang-Mills theory. For generic values of the parameters, these deformations are known to break the SU(3) part of the R-symmetry group down to a discrete subgroup. However, a closer look from the perspective of quantum groups reveals that the Lagrangian is in fact invariant under a certain Hopf algebra which is a non-standard quantum deformation of the algebra of functions on SU(3). Our discussion is motivated by the desire to better understand why these theories have significant differences from N=4 SYM regarding the planar integrability (or rather lack thereof) of the spin chains encoding their spectrum. However, our construction works at the level of the classical Lagrangian, without relying on the language of spin chains. Our approach might eventually provide a better understanding of the finiteness properties of these theories as well as help in the construction of their AdS/CFT duals.Comment: 1+40 pages. v2: minor clarifications and references added. v3: Added an appendix, fixed minor typo

Universal de Sitter solutions at tree-level

Type IIA string theory compactified on SU(3)-structure manifolds with orientifolds allows for classical de Sitter solutions in four dimensions. In this paper we investigate these solutions from a ten-dimensional point of view. In particular, we demonstrate that there exists an attractive class of de Sitter solutions, whose geometry, fluxes and source terms can be entirely written in terms of the universal forms that are defined on all SU(3)-structure manifolds. These are the forms J and Omega, defining the SU(3)-structure itself, and the torsion classes. The existence of such universal de Sitter solutions is governed by easy-to-verify conditions on the SU(3)-structure, rendering the problem of finding dS solutions purely geometrical. We point out that the known (unstable) solution coming from the compactification on SU(2)x SU(2) is of this kind.Comment: 20 pages, 3 figures, v2: added reference

Aportaciones a la flora de Galicia, VIII

Se citan 37 plantas de variado interés para la flora gallega. Se incluyen 8 novedades de carácter regional (Pteris incompleta Cav., Potentilla recta L., Myriophyllum spicatum L., Solanum sisymbrifolium Lam., Knautia integrifolia (L.) Bertol., Senecio inaequidens DC. Melica arrecta G. Kunze y Stipa clausa Trab.), 17 novedades provinciales (Vandenboschia speciosa (Willd.) G. Kunkel, Ranunculus bupleuroides Brot., Silene niceensis All., Armeria transmontana (Samp.) Lawr., Alcea rosea L., Crambe hispanica L., Rorippa microphylla (Rchb.) Hyl., Saxifraga lepismigena Planellas, Cytisus commutatus subsp. merinoi Laínz & M. Laínz, Galega officinalis L., Melilotus spicatus (Sm.) Breistr., Calystegia silvatica (Kit.) Griseb., Orobanche hederae Baucher ex Duby, Aegilops triuncialis L., Eleusine tristachya (Lam.) Lam., Gagea nevadensis Boiss. y Paradisea lusitanica (Cout.) Samp.) y 12 de interés corológico pero que no suponen novedad gallega o provincial (Lycopodiella inundata (L.) Holub., Corydalis cava (L.) Schweigg. & Körte, Quercus cerris L., Genista sanabrensis Valdés Berm., Castrov. & Casaseca, Oenothera speciosa Nutt., Ligustrum vulgare L., Stachys sylvatica L., Antirrhinum meonanthum Hoffmanns. & Link, Cynara cardunculus L., Nardus stricta L., Gagea pratensis (Pers.) Dumort. y Narcissus rupicola Dufour). Como en anteriores aportaciones, cada taxon va acompañado de diversos comentarios que indican su relevancia corológica o ecológica

Aportaciones a la flora de Galicia, IX

En este trabajo se mencionan 53 plantas de diverso interés para la flora de Galicia o zonas próximas. Se incluyen 3 novedades para España (Sesamoides minor (Lange) O. Kuntze x S. purpurascens (L.) G. López, Hedychium gardnerianum Sheppard ex Ker-Gawler y Oxalis incarnata L.) y otra para Portugal (Bromus hordeaceus L. subsp. ferronii (Mabille) P.M. Smith), 3 novedades regionales (Oxalis incarnata L., Antirrhinum latifolium Mill., Sisyrinchium striatum Mill.), 16 novedades provinciales (Ranunculus bulbosus L. subsp. aleae (Willk.) Rouy & Fouc. var. adscendens (Brot.) Pinto da Silva, Ranunculus peltatus subsp. peltatus var. microcarpus Meikle, Dianthus laricifolius subsp. merinoi (M. Laínz) M. Laínz, Spartium junceum L., Sanicula europea L., Tordylium maximum L., Euphorbia flavicoma DC. subsp. occidentalis M. Laínz, Campanula medium L., Centaurea melitensis L., Festuca durandoi Clauson in Billot subsp. capillifolia (Pau ex Willk.) Rivas Ponce, Cebolla & M.B. Crespo var. livida (Hack.) Rivas-Ponce, Cebolla & M.B. Crespo, Phalaris minor Retz, Carex distans L., Carex umbrosa Hornem. subsp. umbrosa) y otras 40 de interés diverso, bien ecológico, corológico o taxonómico. También, y a la luz de más información, eliminamos del catálogo de la flora vascular de Galicia Iberis contracta subsp. welwitschii (Boiss.) Moreno y Arctium lappa L. Se lectotipifica Euphorbia polygalifolia subsp. hirta (Lange) M. Laínz y Senecio doria var. subintegrum Merino

New Mutations in Chronic Lymphocytic Leukemia Identified by Target Enrichment and Deep Sequencing

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease without a well-defined genetic alteration responsible for the onset of the disease. Several lines of evidence coincide in identifying stimulatory and growth signals delivered by B-cell receptor (BCR), and co-receptors together with NFkB pathway, as being the driving force in B-cell survival in CLL. However, the molecular mechanism responsible for this activation has not been identified. Based on the hypothesis that BCR activation may depend on somatic mutations of the BCR and related pathways we have performed a complete mutational screening of 301 selected genes associated with BCR signaling and related pathways using massive parallel sequencing technology in 10 CLL cases. Four mutated genes in coding regions (KRAS, SMARCA2, NFKBIE and PRKD3) have been confirmed by capillary sequencing. In conclusion, this study identifies new genes mutated in CLL, all of them in cases with progressive disease, and demonstrates that next-generation sequencing technologies applied to selected genes or pathways of interest are powerful tools for identifying novel mutational changes

Computational approaches to explainable artificial intelligence: Advances in theory, applications and trends

Deep Learning (DL), a groundbreaking branch of Machine Learning (ML), has emerged as a driving force in both theoretical and applied Artificial Intelligence (AI). DL algorithms, rooted in complex and non-linear artificial neural systems, excel at extracting high-level features from data. DL has demonstrated human-level performance in real-world tasks, including clinical diagnostics, and has unlocked solutions to previously intractable problems in virtual agent design, robotics, genomics, neuroimaging, computer vision, and industrial automation. In this paper, the most relevant advances from the last few years in Artificial Intelligence (AI) and several applications to neuroscience, neuroimaging, computer vision, and robotics are presented, reviewed and discussed. In this way, we summarize the state-of-the-art in AI methods, models and applications within a collection of works presented at the 9th International Conference on the Interplay between Natural and Artificial Computation (IWINAC). The works presented in this paper are excellent examples of new scientific discoveries made in laboratories that have successfully transitioned to real-life applications.MCIU - Nvidia(UMA18-FEDERJA-084

Molecular analysis of the APC and MUTYH genes in Galician and Catalonian FAP families: a different spectrum of mutations?

<p>Abstract</p> <p>Background</p> <p>Familial adenomatous polyposis (FAP) is an autosomal dominant-inherited colorectal cancer syndrome, caused by germline mutations in the <it>APC </it>gene. Recently, biallelic mutations in <it>MUTYH </it>have also been identified in patients with multiple colorectal adenomas and in <it>APC</it>-negative patients with FAP. The aim of this work is therefore to determine the frequency of <it>APC </it>and <it>MUTYH </it>mutations among FAP families from two Spanish populations.</p> <p>Methods</p> <p>Eighty-two unrelated patients with classical or attenuated FAP were screened for <it>APC </it>germline mutations. <it>MUTYH </it>analysis was then conducted in those <it>APC</it>-negative families and in 9 additional patients from a previous study. Direct sequencing, SSCP analysis and TaqMan genotyping were used to identify point and frameshift mutations, meanwhile large rearrangements in the <it>APC </it>gene were screened by multiplex ligation-dependent probe amplification (MLPA).</p> <p>Results</p> <p><it>APC </it>germline mutations were found in 39% of the patients and, despite the great number of genetic variants described so far in this gene, seven new mutations were identified. The two hotspots at codons 1061 and 1309 of the <it>APC </it>gene accounted for 9,4% of the <it>APC</it>-positive families, although they were underrepresented in Galician samples. The deletion at codon 1061 was not found in 19 <it>APC</it>-positive Galician patients but represented 23% of the Catalonian positive families (p = 0,058). The same trend was observed at codon 1309, even though statistical analysis showed no significance between populations. Twenty-four percent of the <it>APC</it>-negative patients carried biallelic <it>MUTYH </it>germline mutations, and showed an attenuated polyposis phenotype generally without extracolonic manifestations. New genetic variants were found, as well as the two hotspots already reported (p.Tyr165Cys and p.Gly382Asp).</p> <p>Conclusion</p> <p>The results we present indicate that in Galician patients the frequency of the hotspot at codon 1061 in <it>APC </it>differs significantly from the Catalonian and also other Caucasian populations. Similar results had already been obtained in a previous study and could be due to the genetic isolation of the Galician population. <it>MUTYH </it>analysis is also recommended for all <it>APC</it>-negative families, even if a recessive inheritance is not confirmed.</p

Artificial intelligence within the interplay between natural and artificial computation:Advances in data science, trends and applications

Artificial intelligence and all its supporting tools, e.g. machine and deep learning in computational intelligence-based systems, are rebuilding our society (economy, education, life-style, etc.) and promising a new era for the social welfare state. In this paper we summarize recent advances in data science and artificial intelligence within the interplay between natural and artificial computation. A review of recent works published in the latter field and the state the art are summarized in a comprehensive and self-contained way to provide a baseline framework for the international community in artificial intelligence. Moreover, this paper aims to provide a complete analysis and some relevant discussions of the current trends and insights within several theoretical and application fields covered in the essay, from theoretical models in artificial intelligence and machine learning to the most prospective applications in robotics, neuroscience, brain computer interfaces, medicine and society, in general.BMS - Pfizer(U01 AG024904). Spanish Ministry of Science, projects: TIN2017-85827-P, RTI2018-098913-B-I00, PSI2015-65848-R, PGC2018-098813-B-C31, PGC2018-098813-B-C32, RTI2018-101114-B-I, TIN2017-90135-R, RTI2018-098743-B-I00 and RTI2018-094645-B-I00; the FPU program (FPU15/06512, FPU17/04154) and Juan de la Cierva (FJCI-2017–33022). Autonomous Government of Andalusia (Spain) projects: UMA18-FEDERJA-084. Consellería de Cultura, Educación e Ordenación Universitaria of Galicia: ED431C2017/12, accreditation 2016–2019, ED431G/08, ED431C2018/29, Comunidad de Madrid, Y2018/EMT-5062 and grant ED431F2018/02. PPMI – a public – private partnership – is funded by The Michael J. Fox Foundation for Parkinson’s Research and funding partners, including Abbott, Biogen Idec, F. Hoffman-La Roche Ltd., GE Healthcare, Genentech and Pfizer Inc

Computational Approaches to Explainable Artificial Intelligence:Advances in Theory, Applications and Trends

Deep Learning (DL), a groundbreaking branch of Machine Learning (ML), has emerged as a driving force in both theoretical and applied Artificial Intelligence (AI). DL algorithms, rooted in complex and non-linear artificial neural systems, excel at extracting high-level features from data. DL has demonstrated human-level performance in real-world tasks, including clinical diagnostics, and has unlocked solutions to previously intractable problems in virtual agent design, robotics, genomics, neuroimaging, computer vision, and industrial automation. In this paper, the most relevant advances from the last few years in Artificial Intelligence (AI) and several applications to neuroscience, neuroimaging, computer vision, and robotics are presented, reviewed and discussed. In this way, we summarize the state-of-the-art in AI methods, models and applications within a collection of works presented at the 9 International Conference on the Interplay between Natural and Artificial Computation (IWINAC). The works presented in this paper are excellent examples of new scientific discoveries made in laboratories that have successfully transitioned to real-life applications

A clinically compatible drug-screening platform based on organotypic cultures identifies vulnerabilities to prevent and treat brain metastasis

We report a medium‐throughput drug‐screening platform (METPlatform) based on organotypic cultures that allows to evaluate inhibitors against metastases growing in situ. By applying this approach to the unmet clinical need of brain metastasis, we identified several vulnerabilities. Among them, a blood–brain barrier permeable HSP90 inhibitor showed high potency against mouse and human brain metastases at clinically relevant stages of the disease, including a novel model of local relapse after neurosurgery. Furthermore, in situ proteomic analysis applied to metastases treated with the chaperone inhibitor uncovered a novel molecular program in brain metastasis, which includes biomarkers of poor prognosis and actionable mechanisms of resistance. Our work validates METPlatform as a potent resource for metastasis research integrating drug‐screening and unbiased omic approaches that is compatible with human samples. Thus, this clinically relevant strategy is aimed to personalize the management of metastatic disease in the brain and elsewhere